Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -644,759 | -463,661 | -328,066 | -239,476 | -186,479 |
| Depreciation Amortization | 83,701 | 36,494 | 24,402 | 11,756 | 8,405 |
| Accounts receivable | N/A | N/A | N/A | -2 | N/A |
| Accounts payable and accrued liabilities | -2,616 | 6,435 | -987 | 1,767 | 1,745 |
| Other Working Capital | 13,688 | -46,758 | -44,257 | 104,921 | -306 |
| Other Operating Activity | 178,178 | 108,316 | 61,128 | 37,510 | 18,021 |
| Operating Cash Flow | $-371,808 | $-359,174 | $-287,780 | $-83,524 | $-158,614 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -3,806 | N/A | 480 | 230,608 | -231,946 |
| PPE Investments | -6,469 | -13,695 | -11,955 | -37,059 | -39,798 |
| Net Acquisitions | -4,438 | 277,104 | 1,844 | N/A | N/A |
| Purchase Sale Intangibles | -2,158 | -3,350 | -597 | -300 | N/A |
| Other Investing Activity | -2,158 | -3,350 | -597 | -300 | 0 |
| Investing Cash Flow | $-16,871 | $260,059 | $-10,228 | $193,249 | $-271,744 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8,425 | -4,440 | -766 | -90 | -12,798 |
| Common Stock Issued | 528,864 | 300,417 | 128,093 | 143,711 | 462,901 |
| Other Financing Activity | 1,093 | 8,143 | 12,806 | 10,724 | 8,437 |
| Financing Cash Flow | $521,532 | $304,120 | $140,133 | $154,345 | $458,540 |
| Exchange Rate Effect | 18,044 | -3,406 | 188 | -307 | N/A |
| Beginning Cash Position | 603,024 | 401,425 | 559,112 | 295,349 | 267,167 |
| End Cash Position | 753,921 | 603,024 | 401,425 | 559,112 | 295,349 |
| Net Cash Flow | $150,897 | $201,599 | $-157,687 | $263,763 | $28,182 |
| Free Cash Flow | |||||
| Operating Cash Flow | -371,808 | -359,174 | -287,780 | -83,524 | -158,614 |
| Capital Expenditure | -6,469 | -13,695 | -11,955 | -37,059 | -39,798 |
| Free Cash Flow | -378,277 | -372,869 | -299,735 | -120,583 | -198,412 |